| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Jun, 2025 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,380 | -2,540 | -1,010 | -5,050 | 0 |
| Net Income Growth | +45.67% | -151.49% | +80.00% | unch | unch |
Polaryx Therapeutics Inc (PLYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Polaryx Therapeutics Inc. is a clinical-stage biotechnology company focused on development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders. Polaryx Therapeutics Inc. is based in PARAMUS, NJ.
Fiscal Year End Date: 12/31